Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
Investing.com - Avalo Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Avalo Therapeutics announced earnings per share of $0.340 on revenue of $14.95M. Analysts polled by Investing.com EPS of $-0.878 on revenue of $1.26M.
Avalo Therapeutics 's are down 11% and is trading at $6.759 , still down 76.43% from its 52 week high of $28.68 set on Monday, November 8, 2021.
Avalo Therapeutics shares gained 0.28% to trade at $6.759 in intra-day trade the report.
Avalo Therapeutics follows other major Healthcare sector earnings this month
Avalo Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar